Anti-Activin B Antibody, Non-Fucosylated (BioBet-511ZP) (CAT#: BioBet-511ZP) Datasheet

Activin B

activin B receptor

Activins are dimeric growth and differentiation factors which belong to the transforming growth factor-beta (TGF-beta) superfamily of structurally related signaling proteins. Activins signal through a heteromeric complex of receptor serine kinases which include at least two type I ( I and IB) and two type II (II and IIB) receptors. These receptors are all transmembrane proteins, composed of a ligand-binding extracellular domain with cysteine-rich region, a transmembrane domain, and a cytoplasmic domain with predicted serine/threonine specificity. Type I receptors are essential for signaling; and type II receptors are required for binding ligands and for expression of type I receptors. Type I and II receptors form a stable complex after ligand binding, resulting in phosphorylation of type I receptors by type II receptors. This gene encodes activin A type I receptor which signals a particular transcriptional response in concert with activin type II receptors. Mutations in this gene are associated with fibrodysplasia ossificans progressive.

activin AB beta polypeptide; Activin B; Activin beta-B chain; INHBB; inhibin beta B chain; inhibin, beta B (activin AB beta polypeptide); inhibin, beta B; Inhibin, beta-2

Plasma membrane

Diseases associated with ACVR1B include Rare Carcinoma Of Pancreas and Pancreatic Cancer.

Its related pathways are Signaling by NODAL and Signaling by GPCR.

The transmembrane serine/threonine kinase activin type 1 receptor and activin type 2 (ACVR2A or ACVR2B) form an activin receptor complex. Transmit activin signals from the cell surface to the cytoplasm, thereby regulating many physiological and pathological processes, including neuronal differentiation and neuron survival, hair follicle development and circulation, FSH production by the pituitary, wound healing, extracellular matrix production, immunosuppression and carcinogenesis . It is also believed that activin has a paracrine or autocrine effect in the development of ovarian follicles. In the receptor complex, type 2 receptors (ACVR2A and/or ACVR2B) act as the main activin receptors, while type 1 receptors (such as ACVR1B) act as downstream transformants of activin signaling. Activin binds to type 2 receptors on the plasma membrane and activates its serine-threonine kinase. Then, the activated type 2 receptor phosphorylates and activates the type 1 receptor (eg ACVR1B). Once activated, type 1 receptors bind to and phosphorylate the SMAD proteins SMAD2 and SMAD3 on the serine residue at the C-terminal tail. Shortly after their binding to activin receptors and subsequent phosphorylation, SMAD2 and SMAD3 are released into the cytoplasm and interact with their co-partner SMAD4. The SMAD complex translocates into the nucleus and mediates activin-induced transcription. The inhibitory SMAD7 recruited to ACVR1B through FKBP1A prevents SMAD2 and SMAD3 from associating with the activin receptor complex, thereby blocking activin signaling. Activin signal transduction is also antagonized by the binding of the IGSF1 inhibin co-receptor to the inhibin B receptor. ACVR1B also phosphorylates TDP2.

Autophosphorylated. Phosphorylated by activin receptor type-2 (ACVR2A or ACVR2B) in response to activin-binding at serine and threonine residues in the GS domain. Phosphorylation of ACVR1B by activin receptor type-2 regulates association with SMAD7. Ubiquitinated. Level of ubiquitination is regulated by the SMAD7-SMURF1 complex. Ubiquitinated.

Protein Based Therapies
Monoclonal antibody (mAb)

IgG

BioBet-511ZP

Human

Human

ADCC-Enhanced anti-Activin B (ActRIIa-mFc) is a non-fucosylated therapeutic biobetter antibody engineered by Creative Biolabs' Afuco™ technology platform.

Bone-related Diseases

Bone-related Diseases